☆ 4.7 Article

Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT)

JOURNAL OF NEUROLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Pharmacology & Pharmacy

Efgartigimod: First Approval

Young-A Heo

Summary: Efgartigimod is a novel drug developed by argenx for the treatment of autoimmune diseases, including myasthenia gravis. It received its first approval in the USA in 2021 and is currently being evaluated and registered in other countries. Numerous clinical studies are also investigating the use of Efgartigimod in various other autoimmune diseases.

DRUGS (2022)

Add to Collection

Article Clinical Neurology

Burden of disease in myasthenia gravis: taking the patient's perspective

Sophie Lehnerer et al.

Summary: Patients with myasthenia gravis (MG) have lower health-related quality of life (HRQoL) compared to the general population, with economic, social, and emotional aspects contributing to the burden of the disease. Factors associated with lower HRQoL in MG patients include female gender, older age, low income, lack of partner, limited daily activities, symptoms of depression, anxiety, fatigue, and perceived low social support.

JOURNAL OF NEUROLOGY (2022)

Add to Collection

Article Clinical Neurology

Long-term outcome in patients with myasthenia gravis: one decade longitudinal study

Ivo Bozovic et al.

Summary: Although a significant number of MG patients were in remission after 10 years, their QoL was still reduced. Factors such as depression and poor disease acceptance may impact the level of QoL in patients.

JOURNAL OF NEUROLOGY (2022)

Add to Collection

Review Clinical Neurology

The humanistic burden of myasthenia gravis: A systematic literature review

Deborah Gelinas et al.

Summary: This systematic literature review aimed to explore the humanistic burden of myasthenia gravis (MG) on patients and caregivers in terms of psychological symptoms and health-related quality of life (HRQoL). The review found that patients with MG had worse HRQoL compared to the general population. Studies on psychological symptoms showed that more severe symptoms and longer hospitalization days were associated with worse depression and anxiety, while fatigue and sleep improved with disease remission and/or improvement.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2022)

Add to Collection

Article Medicine, General & Internal

Quality of Life in Myasthenia Gravis and Correlation of MG-QOL15 with Other Functional Scales

Laura Diez Porras et al.

Summary: This study aimed to evaluate the impact of intensive treatment on the quality of life of patients with myasthenia gravis and identify the demographic and clinical features that influence quality of life. The results showed that quality of life significantly improved after 4 and 6 weeks of treatment. Additionally, the MG-QOL15 questionnaire was found to be correlated with other evaluation scales.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Article Clinical Neurology

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT) : a multicentre, randomised, placebo-controlled, phase 3 trial

James F. Jr Jr Howard et al.

Summary: The study evaluated the safety and efficacy of efgartigimod in patients with generalised myasthenia gravis, showing that it was well tolerated and efficacious. The unique feature of individualized dosing based on clinical response in the study will provide further insights into clinical practice with longer term data from the ongoing open-label extension.

LANCET NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial

James F. Howard et al.

JAMA NEUROLOGY (2020)

Add to Collection

Review Immunology

Antagonism of the Neonatal Fc Receptor as an Emerging Treatment for Myasthenia Gravis

Karissa L. Gable et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Article Clinical Neurology

Prospective study of stress, depression and personality in myasthenia gravis relapses

Anca Bogdan et al.

BMC NEUROLOGY (2020)

Add to Collection

Review Clinical Neurology

A Practical Approach to Managing Patients With Myasthenia Gravis-Opinions and a Review of the Literature

Maria Elena Farrugia et al.

FRONTIERS IN NEUROLOGY (2020)

Add to Collection

Article Health Care Sciences & Services

Gender differences in quality of life among patients with myasthenia gravis in China

Dong Dong et al.

HEALTH AND QUALITY OF LIFE OUTCOMES (2020)

Add to Collection

Article Clinical Neurology

Determinants of Quality of Life in Myasthenia Gravis Patients

Piotr Szczudlik et al.

FRONTIERS IN NEUROLOGY (2020)

Add to Collection

Review Clinical Neurology

Outcome Measures in Clinical Trials of Patients With Myasthenia Gravis

Jan Lykke Scheel Thomsen et al.

FRONTIERS IN NEUROLOGY (2020)

Add to Collection

Review Medicine, General & Internal

A Review of Psychiatric Comorbidity in Myasthenia Gravis

Christina Law et al.

CUREUS JOURNAL OF MEDICAL SCIENCE (2020)

Add to Collection

Article Medicine, General & Internal

Myasthenia gravis

Nils Erik Gilhus et al.

NATURE REVIEWS DISEASE PRIMERS (2019)

Add to Collection

Article Clinical Neurology

Cross-sectional analysis of the Myasthenia Gravis Patient Registry: Disability and treatment

Gary Cutter et al.

MUSCLE & NERVE (2019)

Add to Collection

Review Medicine, General & Internal

Quality of life in refractory generalized myasthenia gravis: A rapid review of the literature

Nathaly Garzon-Orjuela et al.

INTRACTABLE & RARE DISEASES RESEARCH (2019)

Add to Collection

Review Clinical Neurology

Understanding the burden of refractory myasthenia gravis

Christiane Schneider-Gold et al.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2019)

Add to Collection

Article Clinical Neurology

Measuring Clinical Treatment Response in Myasthenia Gravis

Carolina Barnett et al.

NEUROLOGIC CLINICS (2018)

Add to Collection

Article Multidisciplinary Sciences

Factors associated with quality of life of people with Myasthenia Gravis

Ansuk Jeong et al.

PLOS ONE (2018)

Add to Collection

Article Health Care Sciences & Services

Health-related quality of life associated with systemic corticosteroids

Patrick W. Sullivan et al.

QUALITY OF LIFE RESEARCH (2017)

Add to Collection

Article Economics

Instrument-Defined Estimates of the Minimally Important Difference for EQ-5D-5L Index Scores

Nathan S. McClure et al.

VALUE IN HEALTH (2017)

Add to Collection

Article Clinical Neurology

INTERNATIONAL CLINIMETRIC EVALUATION OF THE MG-QOL15, RESULTING IN SLIGHT REVISION AND SUBSEQUENT VALIDATION OF THE MG-QOL15R

Ted M. Burns et al.

MUSCLE & NERVE (2016)

Add to Collection

Review Medicine, General & Internal

Myasthenia Gravis

Nils E. Gilhus

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Health Care Sciences & Services

An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts

M. I. Boldingh et al.

HEALTH AND QUALITY OF LIFE OUTCOMES (2015)

Add to Collection

Article Rheumatology

Drivers of cost and health-related quality of life in patients with systemic lupus erythematosus (SLE): a Swedish nationwide study based on patient reports

C. Bexelius et al.

LUPUS (2013)

Add to Collection

Article Clinical Neurology

Assessment of health-related quality of life in patients with myasthenia gravis in Belgrade (Serbia)

Ivana Z. Basta et al.

NEUROLOGICAL SCIENCES (2012)

Add to Collection

Article Clinical Neurology

The MG Composite A valid and reliable outcome measure for myasthenia gravis

Ted M. Burns et al.

NEUROLOGY (2010)

Add to Collection

© Peeref 2019-2024. All rights reserved.